CSI Market
Sign In | Register

Karuna Therapeutics Inc (KRTX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access KRTX Annual Cash Flow →
This cash flow overview for Karuna Therapeutics Inc spans from Dec 31 2022 to Dec 31 2023, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2023)
12 Months 		(Sep 30 2023) (Jun 30 2023) (Mar 31 2023) (Dec 31 2022)
Operating Activities
Income-433.68
Depreciation & amortization1.70
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation76.60
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Interest Income Expense Nonoperating Net-
Non Cash Investment Income Interest-
Increase Decrease In Right Of Use Assets1.89
Operating Lease Impairment Loss-
Increase Decrease In Operating Lease Liability-1.54
Increase Decrease In Accrued Interest On Investment Securities-2.75
Income taxes147.30
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-0.06
Increase (Decrease) in Accounts Payable4.35
Increase (Decrease) in Accrued Liabilities11.37
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets10.89
Other Working Capital27.48
Other Noncash Income (Expense)0.00
Other net37.97
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-385.82
Investing Activities
Capital Expenditures-2.92
Sale of Capital Items0.00
Short-term Investments Proceeds1,361.09
Payments to Acquire Available-for-sale Securities, Debt0.00
Real Estate Investments0.00
Proceeds From Sale Of Investment Securities-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments-1,518.50
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-160.32
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock51.18
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Redeemable Convertible Preferred Stock Net Of Issuance Of Cost-
Proceeds From Issuance Initial Public Offering Net In Underwriting Discounts And Commissions-
Proceeds From Issuance Of Public Offering Net In Underwriting Discounts And Commissions436.72
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities483.37
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-388.74
Total Cash Flow-62.77
4 historic quarters locked

Sign in to unlock the full Karuna Therapeutics Inc cash flow history.

Sign In Create Free Account

About Karuna Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20231231)
  • Filed with the SEC: February 22, 2024
  • Source: krtx-20231231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-24-018395

Figures are derived from filed reports and may be restated. Historical data is subject to revision.